Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GLYCEROL PHENYLBUTYRATE vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Adjunctive therapy for chronic management of patients with urea cycle disorders involving deficiencies of carbamoyl phosphate synthetase I, ornithine transcarbamylase, or argininosuccinic acid synthetase. It is indicated for all patients requiring therapy for these disorders except those with arginase deficiency.
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
0.8–1 hours (glycerol phenylbutyrate); 1.2–1.5 hours (phenylacetate); clinical context: short half-life requires thrice-daily dosing
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Glycerol phenylbutyrate is metabolized by lipases to phenylbutyrate, which is then beta-oxidized to phenylacetate. Phenylacetate conjugates with glutamine via acyl-Co A synthetase and acyl-Co A:glutamine N-acyltransferase to form phenylacetylglutamine.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: >90% as phenylbutyrate metabolites (mainly phenylacetylglutamine) within 24 hours; fecal: <1%
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
80–90% bound to albumin (phenylacetate and phenylbutyrate)
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
0.2–0.3 L/kg (phenylbutyrate and metabolites); clinical meaning: primarily distributes in extracellular fluid
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Oral: ~100% (prodrug is completely hydrolyzed to phenylbutyrate); intraperitoneal: not used clinically
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR 30-59 m L/min: reduce dose by 50%; GFR 15-29 m L/min: reduce dose by 75%; GFR <15 m L/min: contraindicated.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No dosage adjustment required for hepatic impairment.
450-600 mg/m2/day orally in three divided doses; for children <20 kg, use 450 mg/m2/day; maximum 20 g/day.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Start at low end of dosing range (450 mg/m2/day) and titrate based on renal function and tolerability; monitor for fluid overload.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Monitor plasma ammonia levels, neurotoxicity (somnolence, lethargy, confusion) due to elevated phenylacetate; caution in hepatic or renal impairment; contains phenylalanine; avoid use with valproic acid; may cause hyperammonemia if dosing is incorrect; fluid and electrolyte imbalance; growth retardation in pediatric patients; pancreatic enzyme replacement may be needed.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Known hypersensitivity to glycerol phenylbutyrate or any component; patients with arginase deficiency; patients requiring therapy for hyperammonemia who are unable to swallow capsules or have gastrointestinal obstruction.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Avoid high-protein meals without concurrent nitrogen-scavenging therapy; maintain a protein-restricted diet as prescribed. Do not mix the medication with acidic foods or drinks (e.g., orange juice, tomato juice) as it can cause precipitation.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Glycerol phenylbutyrate is Pregnancy Category C. No adequate studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2 times human exposure; however, fetal toxicity (reduced fetal weight, skeletal variations) occurred at maternally toxic doses. First trimester risk unknown; second and third trimesters: theoretical risk of maternal ammonia control affecting fetal development.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
No data on excretion in human milk; M/P ratio unknown. Due to potential for adverse effects in nursing infants (ammonia elevation if mother has poor control), caution advised. Consider risk-benefit.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No specific dose adjustment recommendations. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; dose titration based on ammonia levels is essential. Monitor ammonia weekly initially, then as needed.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Monitor ammonia levels; glycerol phenylbutyrate is a prodrug that provides phenylbutyrate, which conjugates with glutamine to form phenylacetylglutamine, a nitrogen-scavenging agent excreted in urine. Dosing is weight-based (typically 5-12 m L/m²/day in divided doses) and must be adjusted with hepatic or renal impairment. Avoid use with probenecid as it reduces renal excretion of phenylacetylglutamine. Watch for hypernatremia and metabolic acidosis due to sodium content.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Take with food or formula to reduce gastrointestinal side effects.,Measure dose using the provided oral syringe for accuracy.,Do not mix with acidic beverages (e.g., fruit juice) as it may precipitate.,Contact physician immediately if vomiting occurs within 20 minutes of dosing.,Maintain adequate hydration to ensure urinary excretion of waste nitrogen.,Store at room temperature, do not freeze.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Rimexolone, a corticosteroid with anti-inflammatory activity, may induce the metabolism of glycerol phenylbutyrate via hepatic enzyme induction, particularly CYP3A4. This reduces the conversion of glycerol phenylbutyrate to phenylacetate, decreasing therapeutic efficacy for hyperammonemia management. Clinically, patients may experience elevated ammonia levels, increasing the risk of neurotoxicity and hepatic encephalopathy."
"Concomitant administration of loteprednol, a corticosteroid, with glycerol phenylbutyrate, a nitrogen-binding agent used for urea cycle disorders, may reduce the therapeutic efficacy of glycerol phenylbutyrate. Corticosteroids are known to induce hepatic enzymes involved in drug metabolism, potentially accelerating the clearance of glycerol phenylbutyrate. This interaction could lead to increased ammonia levels and loss of disease control in patients with urea cycle disorders."
"Fluorometholone is a corticosteroid that can induce hepatic enzymes, particularly CYP3A4, potentially accelerating the metabolism of glycerol phenylbutyrate, a prodrug that relies on CYP3A4 for conversion to its active metabolite, phenylacetic acid. This reduction in systemic exposure to phenylacetic acid may decrease the therapeutic efficacy of glycerol phenylbutyrate in managing hyperammonemia in urea cycle disorders. Clinically, this could lead to elevated ammonia levels and breakthrough hyperammonemic episodes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GLYCEROL PHENYLBUTYRATE vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
GLYCEROL PHENYLBUTYRATE is a Ammonia Detoxicant that works by Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GLYCEROL PHENYLBUTYRATE and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GLYCEROL PHENYLBUTYRATE is: 450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GLYCEROL PHENYLBUTYRATE and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GLYCEROL PHENYLBUTYRATE is classified as Category C. Glycerol phenylbutyrate is Pregnancy Category C. No adequate studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2 times human exposure; however, fe. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.